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A B S T R A C T
The objective of this work is to describe the neuropathological findings of a patient clinically presenting with rapidly
progressive nonspecific neurological symptoms suggestive of Creutzfeldt-Jakob disease. Methods used were clinical de-
scription with laboratory analyses, repeated electroencephalogram, cerebral computed tomography, magnetic resonance
imaging studies and details on neuropathological work-up. Neuropathological examination excluded Creutzfeldt-Jakob
disease. By contrast other neurodegenerative changes combining Alzheimer-type pathology and Lewy body pathology
were detected as the most likely substrate of neurological symptoms. Dementia with Lewy bodies should be included in
the differential diagnosis in individuals presenting with rapidly progressive dementia.
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Introduction
Dementia with Lewy bodies (DLB) and Parkinson dis-
ease dementia (PDD) are after Alzheimer’s disease (AD)
the most frequent neurodegenerative disorders. There is
increasing evidence that up to 80% of people with PD will
develop dementia towards the end of their life.While the
neurobiology of movement disorder has been studied in
detail in PD, much less is known about mechanisms un-
derlying the cognitive and behavioral symptoms associ-
ated with DLB and PDD. To date, the best correlate of
cognitive impairment appears to be the presence of corti-
cal Lewy bodies; however new emphasis has been placed
on small aggregates of synuclein1 and cortical and stria-
tal beta-amyloid deposits. Clinically it is important to
recognize DLB with characteristic and often rapidly pro-
gressive symptoms: mental impairment progressing to
dementia, early and prominent visuospatial difficulties,
fluctuation in cognitive function, well-formed visual hal-
lucinations, and spontaneous motor features of parkin-
sonism2. Brainstem or cortical alpha-synuclein immu-
noreactive Lewy bodies are the only features considered
essential for a pathologic diagnosis of dementia with
Lewy bodies, although Lewy-related neurites, Alzheimer
pathology, and spongiosis of upper cortical layers may
also be seen. No standard criteria exist for the neuro-
pathologic diagnosis of Parkinson disease dementia, as
the specificity and sensitivity of the characteristic find-
ings have not been established clearly. Individuals pre-
senting with primary dementia may exhibit neuropatho-
logic features indistinguishable from those of advanced
Parkinson disease (e.g., Braak’s stage 5–6 of PD-related
pathology). Neuropathological diagnostic criteria for Alz-
heimer disease are based on tau-related pathology: neu-
rofibrillary tangles or neuritic plaques. According to
NIA-Reagan criteria, a good correlation between Braak’s
neurofibrillary stage and CERAD plaque score with de-
mentia was found, with relatively good agreement be-
tween these criteria and existing neuropathological me-
thods for diagnosing AD3–5. Sporadic Creutzfeldt-Jakob
disease is a rare fatal neurodegenerative disease charac-
terized by spongiform degeneration of grey matter and
accumulation of pathologic prion protein primarily in the
central nervous system. Its most classical form shows a
quite typical clinical picture with initial subtle changes
in memory and behavior followed by a rapidly progres-
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sive dementia, often with pronounced startle myoclonus,
visual impairment, pyramidal and extrapyramidal or cer-
ebellar signs. Microscopically the characteristic spongi-
form change is seen in the cerebral and cerebellar cortex
and other regions of gray matter, such as caudate, puta-
men and thalamic nuclei, and consists of variable micro-
vacuolation of the neuropil. In advanced disease stages
there is severe neuronal loss and marked reactive astro-
cytosis and microglial activation. Alternative diagnoses
in suspected cases include Alzheimer’s disease, Lewy
body diseases6, vascular encephalopathy, metabolic ence-
phalopathies and viral or limbic encephalitides. Postmor-
tem investigation of brain tissue is mandatory to confirm
the diagnosis of a prion disease.
Clinical Findings
A 60 year old male patient presented various neuro-
logical symptoms about two months prior the hospital-
ization. Patient’s family observed mild cognitive distur-
bances, ataxia, and visuospatial alterations. Routine
laboratory analyses showed no specific findings, but CSF
analysis revealed high level of total proteins. 14-3-3 pro-
tein and tau- protein analysis in CSF was not performed.
Repeated electroencephalograms (EEG) revealed diffuse
attenuation of brain activity with intermittent hypersyn-
chronous delta-waves and repetitive complexes such as
sharp point-wave in its slow variant of 2–3s duration. In
the preteminal phase, he developed febrile status with
»startle« myoclonus. Cerebral computed tomography
(MSCT) showed irregular broadening of periventricular
white matter with hypodensity. Magnetic resonance im-
aging studies (MRI) showed hyperintensities in the cor-
tico subcortical boundary and in white matter (in T2 and
FLAIR sequences). He died 19 days after hospitalization
of interstitial pneumonia. The final clinical diagnosis
was rapidly progressive encephalopathy, most likely due
a to prion disease,fulfilling WHO surveillance criteria for
probable CJD: dementia+ataxia+myoclonus+visuospa-
tial alteration and suggestive EEG.
Autopsy Findings
General macroscopic findings included atherosclero-
sis, predominantly aorta abdominalis, myocardial fibro-
sis and renal sclerosis, interstitial pneumonia with com-
pensatory emphysema as the ultimate cause of death.
The brain was diffusely edematous with a total weight of
1550g. On serial frontal sections, moderate ventricular
enlargement was observed. Right putamen was not well
demarcated from capsula interna and pallidum; also be-
neath the basis of the temporal and occipital lobes dura
was yellow discolorated, as a consequence of chronic, al-
most resorbed subdural haemathoma. Due to the clinical
suspicion of a prion disease, formalin-fixed and paraf-
fin-embedded brain tissue was sent to the Austrian Ref-
erence Center for Human Prion Diseases (ORPE), at the
Institute of Neurology, Medical University in Vienna, for
neuropathological evaluation. Selected brain areas were
basal ganglia including caudate, putamen and pallidum,
pons, medulla oblongata and dura mater.
Neuropathological Findings
Histology showed no characteristic features of a spon-
gioform encephalopathy: there was no spongioform
change, no marked neuronal loss and no significant
gliosis. In addition immunohistochemistry using two dif-
ferent antibodies 12F10 and 3F4 did not reveal patholog-
ical prion protein deposits. So the clinical suspicion of
Creutzfeldt-Jakob disease could not be confirmed. Nev-
ertheless there were other neurodegenerative changes
combining Alzheimer-type pathology and Lewy body pa-
thology. In the temporal and cingular cortex a moderate
density of neuritic plaques was observed in the Biel-
schowsky silver stain. These plaques were composed of
beta-amyloid peptide. Furthermore silver stain and AT8
immunohistochemistry labeled in addition to the neu-
ritic component of neuritic plaques, several tangles and
pretangles in the temporal cortex and nucleus basalis
Meynert (Figure 1), and single tangles in locus coeruleus
and substantia nigra. There was a marked vascular thi-
ckening and remodelling the wall of the leptomemingeal
vessels with some intermingled lymphocytes and macro-
phages in the area of the almost resorbed subdural haem-
orrhage. Moreover, Lewy bodies were already visible in
the HE stain in the locus coeruleus. These were strongly
immunolabelled with antibodies directed against alpha-
-synuclein. In addition to the locus coeruleus, numerous
classical Lewy bodies and some Lewy neurites were de-
tected in the substantia nigra (Figure 2), dorsal nucelus
of the vagus, intermediate reticular zone, raphe, and nu-
cleus basalis Meynert. There was also a moderate amount
of cortical Lewy bodies in the temporal and cingular cor-
tices.
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Fig. 1. Some hyperphosphorylated tau-immunoreactive tangles
in cholinergic neurons of n. basalis Meynert associated with deli-
cate neuropil threads (AT8 ×200).
Summary
The moderate density of neuritic plaques together
with the age of the patient and the reported dementia
would allow the classification into definite Alzheimer’s
disease according to CERAD criteria. The extent and dis-
tribution of neurofibrillary pathology would correspond
at least to stage III according to Braak and Braak classifi-
cation. According to NIA/Reagan Institute criteria there
would be an intermediate likelihood, that dementia had
been due to Alzheimer’s disease lesions. The extent and
distribution of the concomitant alpha-synucleinopathy of
the Lewy body type would correspond at least to a stage 4
of the Parkinson-associated pathology according to
Braak et al; or at least to a limbic stage of diffuse Lewy
body disease (DLB) according to the Newcastle criteria.
Taking into account both the extent of Lewy body related
pathology and Alzheimer type pathology according to the
DLB consortium (2005) there would be an intermediate
likelihood that the pathologic findings could be associ-
ated with the clinical syndrome.
Discussion
We present a patient with Alzheimer and Lewy body-
-related pathology who presented with rapidly progres-
sive dementia, and complex neurological symptoms with
EEG changes that raised the suspicion of CJD. Indeed,
the patient fulfilled clinical surveillance criteria for prob-
able CJD. Nevertheless, this was based solely on EEG re-
sults, but 14-3-3 protein analysis was not performed and
MRI, a sensitive method recently included in diagnostic
criteria7,8, showed no cortical or basal ganglia hyperin-
tensities that are observed in most sCJD subtypes. Simi-
lar clinical presentations between CJD and some forms
of DLB have been previously reported (Tschampa, du
Plessis,Gaig). Tschampa et al.9 analyzed symptoms and
signs of 31 patients with clinical suspicion of CJD but
post-mortem confirmation of AD or DLB. Clinical suspi-
cion of CJD was raised in DLB cases because of rapidly
progressive clinical course with or without focal neuro-
logical signs (70% had myoclonus and limb rigidity) and/
or suggestive EEG (8%).Fifty percent of DLB patients
fulfilled WHO criteria of »possible« and one case of
»probable« sporadic CJD. Recently, Gaig et al.10 pre-
sented a retrospective clinico-pathological study of a sub-
group of DLB patients with rapidly progressive clinical
course (6 cases among 47 subjects with a clinical picture
of DLB).Three of them fulfilled clinical WHO criteria of
»possible« sporadic CJD due to the presence of myoclo-
nus and parkinsonism, but had negative 14-3-3 protein
in CSF and non-typical EEG.The authors could not find
any distinct neuropathological feature of this rapidly
progressive DLB subgroup, nor alpha-synuclein gene
mutations or multiplications.
Due to the lack of a definite in vivo diagnostic test for
most of the currently known neurodegenerative pro-
teinopathies, available methods to delineate the clinical
diagnosis should be combined whenever possible. There-
fore the development of techniques with high sensitivity
and specificity is urgent in terms of therapeutic chal-
lenge. Rapidly progressive diffuse Lewy-body disease with
or without Alzheimer- type pathology should be included
in the differential diagnosis of CJD, especially when use-
ful tests such as 14-3-3 protein in CSF or MRI are nega-
tive.
R E F E R E N C E S
1. FRANCIS PT, J Neurol, 256 Suppl 3 (2009) 280. — 2. MC KEITH
IG, Journal of Alzheimer’s Disease, 9 Suppl 3 (2006) 417. — 3. LIPPA CF,
DUDA JE, GROSSMAN M, HURTIG HI, AARSLAND D, BOEVE BF,
BROOKS DJ, DICKSON DW, DUBOIS B, EMRE M, FAHN S, FARMER
JM, GALASKO D,CALVIN JE, GOETZ CG, GROWDON JH, GWINN-
-HARDY KA, HARDY J, HEUTINK P, IWATSUBO T, KOSAKA K, LEE
VM, LEVERENZ JB, MASLIAH E, MCKEITH IG, NUSSBAUM RL,
OLANOW CV, RAVINA BM, SINGLETON AB, TANNER CM, TROJA-
NOWSKI JQ, WSZOLEK ZK, Neurology, 68 Suppl 11 (2007) 812. — 4.
MURAYAMA S, SAITO Y, Neuropathology, 24 Suppl 3 (2004) 254. — 5.
SHULZ-SCHAEFFER WJ, Acta Neuropathol, 120 Suppl 2 (2010) 131. —
6. MOLLENHAUER B, FORTSL J,DEUSCHL G, STORCH A, OERTEL
W, TRENKWALDER C, DROBNA E, JARIUS C, LANG S,WALDHOR T,
BEMHEIMERH, BUDKAH, Dtsch Arztebl Int, 107 Suppl 39 (2010) 684.
— 7. WHO, Manual for Surveillance of human transmissible spongiform
encephalopathies including variant Creutzfeldt-Jakob disease,WHO,
Geneva, 2003. — 8. ZERR I, KALLENBERG K, SUMMERS DM, RO-
MERO C, TARATUTO A, HEINEMANN U, BREITHAUPT M,VARGES
D, MEISSNER B, LADOGANA A, SCHUUR M, HAIK S, COLINS SJ,
JANSEN GH, STOKIN GB, PIMENTEL J, HEWER E, COLLIE D,
SMITH P, ROBERTS H, BRANDEL JP, VAN DUIJN C, POCCHIARI M,
BEGUE C, CRAS P, WILL RG, SANCHES-JUAN P, Brain, 132 (2009)
2659. — 9. TSCHAMPA HJ, NEUMANN M, ZERR I, HENKEL K,
SCHROTER A, SCHULZ-SCHAEFFER WJ, STEINHOFF BJ, KRETZ-
SCHMAR HA, POSER S, J Neurol Neurosurg Pschiatry, 71 (2001) 33.—
10. GAIG C, VALLDEORIOLA F, GELPI E, EZQUERRAM, LLUFRIU S,
BUONGIORNO M, REY MJ, MARTI MJ, GRAUS F, TOLOSA E, Mov
Disord, 26 (2011) 1316.
A. Krvavica et al.: Alzheimer and Lewy Body Pathology or CJD, Coll. Antropol. 38 (2014) 2: 701–704
703
Fig. 2. Abundant alpha-synuclein immunoreactive Lewy-bodies
and Lewy neurites are detected in dorsal nucleus of vagus and
intermediate reticular zone of medulla oblongata substantia ni-
gra (×400) and n. basalis of Meynert.
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ALZHEIMER I LEWY BODY DEMENCIJA ILI CREUTZFELD-JACOBOVA BOLEST
S A @ E T A K
Na{a namjera je bila opisati neuropataolo{ke promjene kod bolesnika koji se klini~ki manifestirao slikom brzo pro-
gresivne demencije ispunjavaju}i kriterije za vjerojatnu Creutzfeld-Jacobovu bolest (CJD). Neuropatolo{ki pregled je
isklju~io Creutzfeldt-Jacobovu bolest. Imunohistolo{kim metodama su dokazane neuropatolo{ke promjene kombinira-
nog tipa Alzheimerove i Lewyeve demencije kao najvjerojatniji uzro~nici klini~kih simptoma. Preklapanje u klini~kim
simptomima i patolo{kim promjenama bolesnika sa brzo progrediraju}om demencijom mo`e izazvati dijagnosti~ke pro-
bleme, te se uz Creutzfeldt-Jacobovu bolest trebaju diferencijalno dijagnosti~ki uklju~iti Alzheimerova i difuzna Lewye-
va bolest.
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